Dasatinib-induced severe hemorrhagic colitis in chronic myeloid leukemia

Kekilli, MuratTanoğlu, AlpaslanKızıl Çakar, MerihGüney, GüvenHaznedaroğlu, İbrahim C.2019-05-132019-05-132016Kekilli, M., Tanoğlu, A., Kızıl Çakar, M., Güney, G., Haznedaroğlu, İ. C. (2016). Dasatinib-induced severe hemorrhagic colitis in chronic myeloid leukemia. Uluslararasi Hematoloji Onkoloji Dergisi, 26(1), 67-68.1306-133Xhttps://doi.org/10.4999/uhod.740https://hdl.handle.net/11491/2019Dear Editor, Dasatinib is an orally administered, potent, secondline tyrosine kinase inhibitor which is used for treating imatinib resistant or intolerant chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia.eninfo:eu-repo/semantics/openAccess[Belirlenecek]Dasatinib-induced severe hemorrhagic colitis in chronic myeloid leukemiaOther261676810.4999/uhod.740N/AQ4